Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06672939 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

StatusRecruiting
PhasePhase 3
Started2024-11-18
View on ClinicalTrials.gov ↗
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months. Participants who have completed the primary PW01 study (including the 4-week safety follow-up period) will have the opportunity to receive an additional 156 weeks of treatment with orforglipron as well as continuing the lifestyle intervention.

Amendment history 1 change detected by DataLookout

2026-08-25
Trial sites reduced: 38 → 34 locations
Trial Details
NCT Number NCT06672939
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight
Enrollment 150 participants
Start Date 2024-11-18
Primary Completion 2027-12 (estimated)
Study Completion 2031-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-24